News >

Blackwell Sheds Light on Recent Advances in HER2+ Breast Cancer

Angelica Welch
Published: Wednesday, Feb 14, 2018

Kimberly L. Blackwell, MD

Kimberly L. Blackwell, MD
The HER2-positive breast cancer space has seen a wave of novel treatments and FDA approvals.

, Blackwell, a medical oncologist at Duke Cancer Institute, discussed these novel agents and other recent advancements in the treatment paradigm of HER2-positive breast cancer.

OncLive: What are your thoughts on the data reported with tucatinib in patients with brain metastases?

Blackwell: Tucatinib is one of the most exciting agents out there in the investigative space that is trying to improve on current therapies for HER2-positive breast cancer. The data out of the 2017 San Antonio Breast Cancer Symposium evaluated giving tucatinib, a small molecule inhibitor very specific against HER2, prior to a patient receiving whole-brain radiotherapy in patients who are facing brain metastases.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: PARP Inhibition in Breast Cancer: Practical Methods to Interpret and Apply the Evidence for Your PatientsAug 30, 20191.5
Provider and Caregiver Connection™: Addressing Patient Concerns in the Management of Premenopausal Breast CancerAug 31, 20192.0
Publication Bottom Border
Border Publication